SPECIAL NOTICE
A -- Chemical Optimization and Preclinical Development of Molecular-Targeted Anticancer Drug Leads
- Notice Date
- 11/19/2004
- Notice Type
- Special Notice
- NAICS
- 325411
— Medicinal and Botanical Manufacturing
- Contracting Office
- Department of Health and Human Services, National Institutes of Health, National Cancer Institute, Bldg 427, Room 12, Frederick, MD, 21702
- ZIP Code
- 21702
- Solicitation Number
- Reference-Number-BJG-01685u1
- Description
- The National Cancer Institute (NCI)-Developmental Therapeutics Program (DTP) - Screening Technologies Branch (STB) seeks Cooperative Research and Development Agreement (CRADA) collaborator(s) to participate in the optimization of small molecule, molecular-targeted anticancer screening leads for potency and pharmaceutical properties consistent with clinical developmenta. The leads have been identified by the NCI-STB using high-throughput screening and preliminary structure/activity study of 140,000 samples from an NCI repository addressing a number of antitumor molecular targets of potential therapeutic significance. Potential Areas if Application: Antitumor agents. Specifically, opportunities are available to optimize antitumor leads for inhibition of Hypoxia Inducible Factor-1 (HIF-1) alpha signaling and for inducers of the CCAAT/Enhancer Binding Protein (CEBP- ) signaling pathway. Main Advantages of the Technology: Lead compounds possess distinct mechanisms of antitumor activities. Current State of Development: In vitro evaluation and preliminary structure/activity studies on-going at NCI for existing leads. Further R&D Requireda: Initially, a medicinal chemistry partner is sought to identify and resolve potential structural problems / features thus optimizing lead compound(s) for activity, potency, formulation, stability, metabolism, toxicity, absorption/distribution etc. Secondary or in vivo biological testing would be carried out by the NCI-Screening Technologies Branch. In a second stage, in vivo active compounds will be subjected to additional analysis and analogs will be synthesized to further optimize structure/activity properties. Pertinent References: Federal Register, November 8th, 2002, Volume 67, No. 217, pp. 68143-68144. "National Cancer Institute: Chemical Optimization of Molecular- Targeted Anticancer, Antiviral and Antimicrobial Drug Leads". Contact Information: Bjarne Gabrielsen, Ph.D., Technology Transfer Branch, NCI-Frederick, Fairview Center, Suite 500 1003 W. 7th Street, Frederick, MD 21701-8512. Phone: (301) 846-5465; email: bjg@nih.gov. Last Updated 11/10/2004
- Record
- SN00710700-W 20041121/041119211639 (fbodaily.com)
- Source
-
FedBizOpps.gov Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |